Safety and efficacy of montelukast as adjunctive therapy for treatment of asthma in elderly patients

Nicola Scichilone, Salvatore Battaglia, Alida Benfante, Vincenzo BelliaDipartimento Biomedico di Medicina Interna e Specialistica, University of Palermo, Palermo, ItalyAbstract: Asthma is a disease of all ages. This assumption has been challenged in the past, because of several cultural and scientif...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Scichilone N, Battaglia S, Benfante A, Bellia V
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Leukotriene asthma treatment airway inflammation aging Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/5c046ddbfa854ddeb5efc35e549a2542
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5c046ddbfa854ddeb5efc35e549a2542
record_format	dspace
spelling	oai:doaj.org-article:5c046ddbfa854ddeb5efc35e549a25422021-12-02T00:41:34ZSafety and efficacy of montelukast as adjunctive therapy for treatment of asthma in elderly patients1178-1998https://doaj.org/article/5c046ddbfa854ddeb5efc35e549a25422013-10-01T00:00:00Zhttps://www.dovepress.com/safety-and-efficacy-of-montelukast-as-adjunctive-therapy-for-treatment-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Nicola Scichilone, Salvatore Battaglia, Alida Benfante, Vincenzo BelliaDipartimento Biomedico di Medicina Interna e Specialistica, University of Palermo, Palermo, ItalyAbstract: Asthma is a disease of all ages. This assumption has been challenged in the past, because of several cultural and scientific biases. A large body of evidence has accumulated in recent years to confirm that the prevalence of asthma in the most advanced ages is similar to that in younger ages. Asthma in the elderly may show similar functional and clinical characteristics to that occurring in young adults, although the frequent coexistence of comorbid conditions in older patients, together with age-associated changes in the human lung, may lead to more severe forms of the disease. Management of asthma in the elderly follows specific guidelines that apply to all ages, although most behaviors are pure extrapolation of what has been tested in young ages. In fact, age has always represented an exclusion criterion for eligibility to clinical trials. This review focuses specifically on the safety and efficacy of leukotriene modifiers, which represent a valid option in the treatment of allergic asthma, both as an alternative to first-line drugs and as add-on treatment to inhaled corticosteroids. Available studies specifically addressing the role of montelukast in the elderly are scarce; however, leukotriene modifiers have been demonstrated to be safe in this age group, even though cases of acute hepatitis and occurrence of Churg-Strauss syndrome have been described in elderly patients; whether this is associated with age is to be confirmed. Furthermore, leukotriene modifiers provide additional benefit when added to regular maintenance therapy, not differently from young asthmatics. In elderly patients, the simpler route of administration of leukotriene modifiers, compared with the inhaled agents, could represent a more effective strategy in improving the outcomes of asthma therapy, given that unintentional nonadherence with inhalation therapy represents a complex problem that may lead to significant impairment of asthma symptom control.Keywords: leukotriene antagonists, asthma, treatment, airway inflammation, agingScichilone NBattaglia SBenfante ABellia VDove Medical PressarticleLeukotrieneasthma treatmentairway inflammationagingGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 8, Pp 1329-1337 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Leukotriene asthma treatment airway inflammation aging Geriatrics RC952-954.6
spellingShingle	Leukotriene asthma treatment airway inflammation aging Geriatrics RC952-954.6 Scichilone N Battaglia S Benfante A Bellia V Safety and efficacy of montelukast as adjunctive therapy for treatment of asthma in elderly patients
description	Nicola Scichilone, Salvatore Battaglia, Alida Benfante, Vincenzo BelliaDipartimento Biomedico di Medicina Interna e Specialistica, University of Palermo, Palermo, ItalyAbstract: Asthma is a disease of all ages. This assumption has been challenged in the past, because of several cultural and scientific biases. A large body of evidence has accumulated in recent years to confirm that the prevalence of asthma in the most advanced ages is similar to that in younger ages. Asthma in the elderly may show similar functional and clinical characteristics to that occurring in young adults, although the frequent coexistence of comorbid conditions in older patients, together with age-associated changes in the human lung, may lead to more severe forms of the disease. Management of asthma in the elderly follows specific guidelines that apply to all ages, although most behaviors are pure extrapolation of what has been tested in young ages. In fact, age has always represented an exclusion criterion for eligibility to clinical trials. This review focuses specifically on the safety and efficacy of leukotriene modifiers, which represent a valid option in the treatment of allergic asthma, both as an alternative to first-line drugs and as add-on treatment to inhaled corticosteroids. Available studies specifically addressing the role of montelukast in the elderly are scarce; however, leukotriene modifiers have been demonstrated to be safe in this age group, even though cases of acute hepatitis and occurrence of Churg-Strauss syndrome have been described in elderly patients; whether this is associated with age is to be confirmed. Furthermore, leukotriene modifiers provide additional benefit when added to regular maintenance therapy, not differently from young asthmatics. In elderly patients, the simpler route of administration of leukotriene modifiers, compared with the inhaled agents, could represent a more effective strategy in improving the outcomes of asthma therapy, given that unintentional nonadherence with inhalation therapy represents a complex problem that may lead to significant impairment of asthma symptom control.Keywords: leukotriene antagonists, asthma, treatment, airway inflammation, aging
format	article
author	Scichilone N Battaglia S Benfante A Bellia V
author_facet	Scichilone N Battaglia S Benfante A Bellia V
author_sort	Scichilone N
title	Safety and efficacy of montelukast as adjunctive therapy for treatment of asthma in elderly patients
title_short	Safety and efficacy of montelukast as adjunctive therapy for treatment of asthma in elderly patients
title_full	Safety and efficacy of montelukast as adjunctive therapy for treatment of asthma in elderly patients
title_fullStr	Safety and efficacy of montelukast as adjunctive therapy for treatment of asthma in elderly patients
title_full_unstemmed	Safety and efficacy of montelukast as adjunctive therapy for treatment of asthma in elderly patients
title_sort	safety and efficacy of montelukast as adjunctive therapy for treatment of asthma in elderly patients
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/5c046ddbfa854ddeb5efc35e549a2542
work_keys_str_mv	AT scichilonen safetyandefficacyofmontelukastasadjunctivetherapyfortreatmentofasthmainelderlypatients AT battaglias safetyandefficacyofmontelukastasadjunctivetherapyfortreatmentofasthmainelderlypatients AT benfantea safetyandefficacyofmontelukastasadjunctivetherapyfortreatmentofasthmainelderlypatients AT belliav safetyandefficacyofmontelukastasadjunctivetherapyfortreatmentofasthmainelderlypatients
_version_	1718403556474617856

Safety and efficacy of montelukast as adjunctive therapy for treatment of asthma in elderly patients

Ejemplares similares